Edwards Lifesciences Corporation (EW) has seen a lot of financial activity recently. Notable institutions, including US Bancorp DE and Citigroup Inc., sold significant amounts of their EW shares. Conversely, Mitsubishi UFJ Asset Management Co. Ltd., Washington Trust Advisors Inc., and HighTower Advisors LLC, bought considerable numbers of EW shares. Moreover, an EW officer sold 24,000 shares, and Edwards Lifesciences CVP, Bobo, sold $2M in stock. The corporation plans to reach 2 million underserved heart patients by 2030 and expects to expand its atrial fibrillation reach with a 2026 product launch. Analysts suggest a shift in the EW investment story after mixed revisions, but they also note EW's financial metrics as a winning formula. EW's positive Q4 update drew favorable analyst views, and institutional investors own 88% of EW. The company is also looking to present at prominent healthcare conferences. A few analysts offer a bull case theory amidst a possible 17.8% undervaluation. For investors considering EW shares, $1000 invested 20 years ago would show considerable growth today. Overall, despite some share sales, EW exhibits robust growth potential, pointing potentially towards a profit surge.
Edwards Lifesciences Corp EW News Analytics from Fri, 25 Jul 2025 07:00:00 GMT to Sat, 28 Feb 2026 13:45:06 GMT -
Rating 7
- Innovation 7
- Information 8
- Rumor 5
